Viatris Inc. — Ethics Grade C+

Viatris Inc. receives an overall ethics grade of C+ (58/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 45
• privacy: 80
• consumer: 35
• environment: 72
• humanRights: 68

Documented incidents (3)

• EpiPen Price Gouging (high, 2016) — Prior to the Viatris merger, Mylan (the core component of Viatris) increased the price of the life-saving EpiPen by over 400%, from roughly $100 to over $600. The CEO at the time faced a Congressional hearing regarding corporate greed and patient access.
• Mass Global Layoffs (medium, 2020) — Immediately following the merger of Mylan and Upjohn, the company announced it would cut 20% of its global workforce and close 15 manufacturing sites to achieve cost synergies. The move was heavily criticized in communities where it was the primary employer.
• Generic Drug Price Fixing (high, 2020) — The company was implicated in a major multistate lawsuit alleging that dozens of generic drug makers conspired to artificially inflate prices for broad categories of medicines, including treatments for diabetes and cancer.

Documented good deeds

• HIV Medicine Access — Ranked among the top companies in the Access to Medicine Index for providing affordable pediatric HIV medications in low-and-middle-income countries.

Ethical alternatives

• Gilead Sciences — Better record on R&D investment relative to stock buybacks and fewer price-fixing allegations.